A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

June 26, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Cystic Fibrosis
Interventions
DRUG

ETD001

Twice daily doses

DRUG

Placebo

Twice daily doses

Trial Locations (21)

13353

Charité Universtaetsmedizin, Berlin

16147

IRCCS Istituto Giannina Gaslini, Genova

20122

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico, Milan

31059

Hôpitaux de Toulouse, Toulouse

34295

CHU de Montpellier, Montpellier

37126

Azienda Ospedaliera Universitaria Integrata Verona, Verona

45239

Westdeutsches Lungenzentrum am Universitätsklinikum, Essen

50139

Azienda Ospedaliera Universitaria Meyer, Florence

50924

CF-Studienzentrum Universitätsklinikum Köln, Cologne

60590

Universitätsklinikum Frankfurt, Frankfurt

60596

IKF Pneumologie, Frankfurt

69495

Hospices Civils de Lyon, Lyon

75014

Hôpital Cochin, Paris

80336

LMU Kinikum, Munich

00165

Ospedale Pediatrico Bambino Gesù, Roma

BT9 7AB

Belfast Health and Social Care Trust, Belfast

CB2 0AY

Royal Papworth Hospital, Cambridge

CF64 2XX

All Wales Adult CF Centre, Cardiff

G51 4TR

Queen Elizabeth University Hospital West of Scotland CF Service, Glasgow

SW3 6LL

Royal Brompton Hospital, London

SO16 6YD

Southampton General Hospital, Southampton

Sponsors
All Listed Sponsors
lead

Enterprise Therapeutics Ltd

INDUSTRY

NCT06478706 - A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis | Biotech Hunter | Biotech Hunter